FDA Causes More CBD Market Ambiguity | Supplement Industry Implications | Sibyl Swift, Ph.D. (cbdMD) Interview

Pivotal is an interview-style segment that tackles topics in consumer packaged goods (CPG) and fast moving consumer goods (FMCG) from the business leaders that live it EVERY DAY! After years of keeping the industry in suspense, the FDA recently concluded that CBD can’t be regulated under existing frameworks for dietary supplements and foods/beverages. What? Why? Huh? While I read the FDA announcement both at face value and between the lines, the current state of CBD within the CPG industry is the type of nuanced subject matter that requires additional expertise if I’m going to reach the level of insights I believe you deserve. So, with a multi-year background at the FDA and current C-Suite experience at the publicly traded CBD supplement company cbdMD (NYSE: YCBD), I knew Sibyl Swift, Ph.D. would be the perfect person to help me with this content. Beyond the ins and outs of the recent FDA announcement, we talked about our confidence in Congress to help, how the DEA is getting involved with enforcement of synthetic cannabinoids, and what the Twitter advertising announcement might mean for allowability of other business tools in the near future. Those are just some of the fascinating topics we chatted about in this episode... Sibyl Swift, Ph.D. LinkedIn FOLLOW ME ON MY SOCIAL MEDIA ACCOUNTS LINKEDIN - https://www.linkedin.com/in/joshuaschallmba TWITTER - https://www.twitter.com/joshua_schall INSTAGRAM - https://www.instagram.com/joshua_schall FACEBOOK - https://www.facebook.com/jschallconsulting MEDIUM - https://www.medium.com/@joshuaschall